EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Emerging Cross-Resistance to Cefiderocol and Ceftazidime-Avibactam in KPC-Producing Klebsiella pneumoniae During Ceftazidime-Avibactam Therapy

Cristina Riazzo iD, Cristina Elías-López iD, Montserrat Muñoz-Rosa iD, Cristina Arjona-Torres iD, Tania Blanco-Martín, Isabel Machuca, Julian Torre-Cisneros iD, Irene Gracia-Ahufinger iD, Nicolas Kieffer iD, Jorge Arca-Suárez iD, Luis Martínez-Martínez iD

Antibiotics · 17.07.2026 · 15 (7) · 701

DOI: 10.3390/antibiotics15070701 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibiotics, online erschienen am 17.07.2026. Verfasst von Cristina Riazzo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Maimonides Biomedical Research Institute of Cordoba, Reina Sofía University Hospital, University of Cordoba (IMIBIC/HURS/UCO), 14004 Cordoba, Spain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institute of Health Carlos III, Instituto de Salud Carlos III, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Ceftazidime-avibactam (CAZ/AVI) and cefiderocol (FDC) retain activity against most clinical isolates of KPC-producing Klebsiella pneumoniae (KPC-Kp). Nevertheless, the emergence of cross-resistance between both agents has become an increasing clinical concern. In this study, the development of resistance to both CAZ/AVI and FDC was retrospectively investigated in KPC-Kp isolates recovered from patients treated with CAZ/AVI between 2014 and 2023.

Methods

Twenty-two isolates (pre- and post-therapy) obtained from nine patients were included. Demographic and clinical data were collected. FDC susceptibility testing was determined for both clinical isolates and E. coli TOP10 transformants by reference broth microdilution using iron-depleted medium, and MICs were interpreted according to EUCAST breakpoints. Resistance mechanisms were characterized using whole genome sequencing.

Results

Cross-resistance to both CAZ/AVI and FDC emerged in six patients (66.7%) during CAZ/AVI therapy, after a median treatment duration of 12.8 ± 7.6 days. The presence of different KPC-3 variants in the CAZ/AVI-FDC resistant isolates was revealed by genomic analysis. Furthermore, the role of KPC-28, KPC-31, KPC-47, KPC-94, KPC-95, and KPC-148 in mediating reduced susceptibility to CAZ/AVI and FDC was confirmed by AST of transformants carrying blaKPC variants. However, differences in MIC values compared with those obtained for the corresponding clinical isolates supported the relevance of additional mechanisms of co-resistance. The presence of ferric citrate transport (FEC) system was also associated with higher FDC MICs. Mutations in genes coding siderophore-iron transporter, PBPs, sensor histidine kinase or Tol-Pal system were also found in some of the isolates.

Conclusions

These findings highlight the ability of KPC-Kp to develop co-resistance to both CAZ/AVI and FDC during CAZ/AVI therapy.

Schlagwörter

Stichwörter der Autor:innen

KPCKlebsiella pneumoniaecefiderocolceftazidime/avibactam

Autor:innen und Institutionen

  • Maimonides Biomedical Research Institute of Cordoba, Reina Sofía University Hospital, University of Cordoba (IMIBIC/HURS/UCO), 14004 Cordoba, Spain.
  • Unit of Microbiology, Reina Sofía University Hospital, 14004 Cordoba, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
  • Servicio de Microbiología Clínica and Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidade da…
  • Infectious Diseases Service, Reina Sofía University Hospital, 14004 Cordoba, Spain.
  • Department of Agricultural Chemistry, Soil Sciences and Microbiology, University of Cordoba, 14071 Cordoba, Spain.

ORCID-Profile: Cristina Riazzo, Cristina Elías-López, Montserrat Muñoz-Rosa, Cristina Arjona-Torres, Julian Torre-Cisneros, Irene Gracia-Ahufinger, Nicolas Kieffer, Jorge Arca-Suárez, Luis Martínez-Martínez

Förderung

  • Institute of Health Carlos III
  • Instituto de Salud Carlos III
  • European Union
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas
  • ISCIII Juan Rodés program
  • ISCIII Miguel Servet program

Zitieren

APA

Riazzo, C., Elías-López, C., Muñoz-Rosa, M., Arjona-Torres, C., Blanco-Martín, T., Machuca, I., Torre-Cisneros, J., Gracia-Ahufinger, I., Kieffer, N., Arca-Suárez, J., & Martínez-Martínez, L. (2026). Emerging Cross-Resistance to Cefiderocol and Ceftazidime-Avibactam in KPC-Producing Klebsiella pneumoniae During Ceftazidime-Avibactam Therapy. Antibiotics, 15(7), 701. https://doi.org/10.3390/antibiotics15070701

Vancouver

Riazzo C, Elías-López C, Muñoz-Rosa M, Arjona-Torres C, Blanco-Martín T, Machuca I, et al. Emerging Cross-Resistance to Cefiderocol and Ceftazidime-Avibactam in KPC-Producing Klebsiella pneumoniae During Ceftazidime-Avibactam Therapy. Antibiotics. 2026;15(7):701. doi:10.3390/antibiotics15070701

BibTeX
@article{Riazzo2026,
  author = {Riazzo, Cristina and Elías-López, Cristina and Muñoz-Rosa, Montserrat and Arjona-Torres, Cristina and Blanco-Martín, Tania and Machuca, Isabel and Torre-Cisneros, Julian and Gracia-Ahufinger, Irene and Kieffer, Nicolas and Arca-Suárez, Jorge and Martínez-Martínez, Luis},
  title = {Emerging Cross-Resistance to Cefiderocol and Ceftazidime-Avibactam in KPC-Producing Klebsiella pneumoniae During Ceftazidime-Avibactam Therapy},
  journal = {Antibiotics},
  year = {2026},
  volume = {15},
  number = {7},
  pages = {701},
  doi = {10.3390/antibiotics15070701}
}
Kostenlos starten →